Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Xetra  >  4Sc AG    VSC   DE000A14KL72

4SC AG (VSC)
My previous session
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsTweets
OFFRE

4SC AG: Preliminary announcement of the publication of financial reports according to Articles 114, 115, 117 of the WpHG [the German Securities Act]

share with twitter share with LinkedIn share with facebook
share via e-mail
0
03/13/2018 | 06:25pm CEST

DGAP Preliminary announcement financial reports: 4SC AG / Preliminary announcement on the disclosure of financial statements
4SC AG: Preliminary announcement of the publication of financial reports according to Articles 114, 115, 117 of the WpHG [the German Securities Act]

13.03.2018 / 18:22
Preliminary announcement of the publication of financial reports according to Articles 114, 115, 117 of the WpHG [the German Securities Act] transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


4SC AG hereby announces that the following financial reports shall be disclosed :

Report: Annual financial report
Date of disclosure / German: March 21, 2018 Date of disclosure / English: March 21, 2018 German: https://www.4sc.de/investoren/investoren-informationen/finanzberichte/ English: https://www.4sc.com/investors/investor-information/financial-reports/



13.03.2018 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: 4SC AG
Fraunhoferstr. 22
82152 Planegg-Martinsried
Germany
Internet: www.4sc.com

 
End of News DGAP News Service

663775  13.03.2018 

fncls.ssp?fn=show_t_gif&application_id=663775&application_name=news&site_id=zonebourse

© EQS 2018
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on 4SC AG
09/204SC AG : Domatinostat plus chemotherapy - Overcoming drug resistance
EQ
09/124SC AG : 6 upcoming conferences and roadshows
EQ
08/154SC AG : FDA approves IND application for domatinostat (4SC-202) in melanoma
EQ
08/094SC : provides Q2 and H1 2018 update
EQ
08/024SC AG : Conference call to be hosted on 9 August 2018 to present the half-year ..
EQ
07/314SC : First patient enrolled in 2nd dose cohort of Phase Ib/II study SENSITIZE o..
EQ
07/184SC AG : Stifel Nicolaus Europe initiates research coverage on 4SC with a buy ra..
EQ
07/034SC AG : Positive safety review of 4SC's Phase Ib/II SENSITIZE study of domatino..
EQ
06/284SC AG : New data supports resminostat's mechanism of action in CTCL maintenance..
EQ
05/224SC AG : 9 upcoming conferences and roadshows
EQ
More news
News from SeekingAlpha
08/104sc Ag 2018 Q2 - Results - Earnings Call Slides 
02/064SC (FSCGF) Presents At BioCapital Europe 2018 - Slideshow 
02/033 THINGS IN BIOTECH YOU SHOULD LEARN : February 2, 2018 
20164SC AG Presents at The German Equity Forum 2016 
Financials (€)
Sales 2018 5,30 M
EBIT 2018 -14,8 M
Net income 2018 -14,8 M
Finance 2018 29,1 M
Yield 2018 -
P/E ratio 2018 -
P/E ratio 2019
EV / Sales 2018 18,4x
EV / Sales 2019 24,5x
Capitalization 127 M
Chart 4SC AG
Duration : Period :
4Sc AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends 4SC AG
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 2
Average target price 4,98 €
Spread / Average Target 20%
EPS Revisions
Managers
NameTitle
Jason Loveridge Chief Executive Officer
Clemens M. Doppler Chairman-Supervisory Board
Susanne Danhauser-Riedl Chief Medical Officer
Manfred Rüdiger Member-Supervisory Board
Helmut Jeggle Member-Supervisory Board
Sector and Competitors
1st jan.Capitalization (M$)
4SC AG-14.37%149
CELLTRION, INC.--.--%33 388
IQVIA HOLDINGS INC30.32%25 763
LONZA GROUP18.80%24 291
INCYTE CORPORATION-29.69%14 156
SEATTLE GENETICS, INC.45.35%12 348